Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03350516
Recruitment Status : Recruiting
First Posted : November 22, 2017
Last Update Posted : April 27, 2021
Sponsor:
Collaborators:
St. John's Research Institute
Ifakara Health Institute
Africa Academy for Public Health
Information provided by (Responsible Party):
Wafaie Fawzi, Harvard School of Public Health

Brief Summary:

The World Health Organization currently recommends that pregnant women in populations with low calcium intake receive daily calcium supplementation (1500 - 2000 mg) divided into three doses which are preferably taken at mealtimes, in addition to daily iron folic-acid supplements. Despite proven efficacy and the WHO recommendation, calcium supplementation in pregnancy is not standard of care in the vast majority of low-income and middle-income countries. Two important barriers to implementation are the cost of the supplements and complexity of the suggested calcium dosing schedule. A lower dose of calcium (500 mg) administered as a single dose has been shown to be beneficial in several trials, and if found to be as effective as the 1500 mg supplementation regimen, it may help overcome these barriers and increase individual and health system adoption.

The Investigators will conduct two parallel, individually randomized, double blind non-inferiority trials in India and Tanzania. Participating pregnant woman will be randomized to either 1500 mg or 500 mg calcium supplementation. The India and Tanzania trials are independently powered for the primary outcomes of i) preeclampsia and ii) preterm birth. The India and Tanzania sites will each enroll 11,000 participants.


Condition or disease Intervention/treatment Phase
Pregnancy Related Dietary Supplement: Daily 500 mg elemental calcium as calcium carbonate Dietary Supplement: Daily1500 mg elemental calcium as calcium carbonate Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Demonstrating Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy for Reducing Preeclampsia and Neonatal Outcomes
Actual Study Start Date : November 30, 2018
Estimated Primary Completion Date : September 1, 2022
Estimated Study Completion Date : September 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Arm Intervention/treatment
Experimental: Daily 500 mg Calcium Dietary Supplement: Daily 500 mg elemental calcium as calcium carbonate
Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.

Active Comparator: Daily1500 mg Calcium (Standard dose) Dietary Supplement: Daily1500 mg elemental calcium as calcium carbonate
Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.




Primary Outcome Measures :
  1. Proportion of pregnant women with incident preeclampsia [ Time Frame: Gestational week 20 to Delivery ]
  2. Proportion of preterm birth [ Time Frame: Birth ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Nulliparous
  • Attending first ANC visit at study clinics
  • Pregnant women <20 weeks
  • ≥ 18 years old
  • Intending to stay in study area until 6 weeks post delivery
  • Provides informed consent

Exclusion Criteria:

  • History or signs and/or symptoms of nephrolithiasis
  • Prior diagnosis of parathyroid disorder or thyroidectomy
  • Diseases that require digoxin, phenytoin, or tetracycline therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03350516


Contacts
Layout table for location contacts
Contact: Wafaie W Fawzi, MBBS, DrPH 617-432-5299 mina@hsph.harvard.edu
Contact: Christopher R Sudfeld, ScD 617-432-5051 csudfeld@hsph.harvard.edu

Locations
Layout table for location information
India
St. John's Research Institute Recruiting
Bangalore, India
Contact: Anura Kurpad, MD, PhD       a.kurpad@sjri.res.in   
Tanzania
Africa Academy for Public Health Recruiting
Dar Es Salaam, Tanzania
Contact: Mary Mwanyika-Sando, MD, MPH       mmwanyika.sando@gmail.com   
Ifakara Health Institute Recruiting
Dar Es Salaam, Tanzania
Contact: Honorati Masanja, PhD       hmasanja@ihi.or.tz   
Sponsors and Collaborators
Harvard School of Public Health
St. John's Research Institute
Ifakara Health Institute
Africa Academy for Public Health
Investigators
Layout table for investigator information
Principal Investigator: Wafaie W Fawzi, MBBS, DrPH Harvard School of Public Health
Layout table for additonal information
Responsible Party: Wafaie Fawzi, Richard Saltonstall Professor of Population Sciences, Professor of Nutrition, Epidemiology, and Global Health, Chair of the Department of Global Health and Population, Harvard School of Public Health
ClinicalTrials.gov Identifier: NCT03350516    
Other Study ID Numbers: OPP1172660
First Posted: November 22, 2017    Key Record Dates
Last Update Posted: April 27, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium, Dietary
Calcium Carbonate
Calcium
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents